Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01926626 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers
A Phase 2 study of Nicotine Dependence, sponsored by Jed E. Rose.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 3
- Study locations
NCT01926626 is a Phase 2 study of Nicotine Dependence that has completed, run by Jed E. Rose. The registered enrollment target is 76 participants, below the 186-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (59% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT01926626, a Phase 2 study of Nicotine Dependence, has completed, sponsored by Jed E. Rose.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 3
- Study locations
Study Summary
The proposed study will assess the efficacy of moclobemide, a selective, reversible MAO-A inhibitor, in facilitating smoking cessation in treatment-seeking female smokers. This rationale is based on several findings from previous work: 1) cigarette smoke contains constituents that inhibit both forms of the enzyme monoamine oxidase (MAO-A and MAO-B); 2) that severity of depression symptoms after smoking abstinence is correlated with the level of MAO-A inhibition previously obtained from smoking; 3) moclobemide, an MAO-A inhibitor was found efficacious in a smoking cessation treatment trial (Berlin et al., 1995); and 4) women show a greater association between smoking and depression than men and women smokers in our previous trials report smoking to alleviate symptoms of depression to a greater extent than men.
Conditions Studied
Interventions
- DRUG Nicotine Patch
- DRUG Moclobemide
Study Locations (3)
North Carolina
- Duke Center for Smoking Cessation - Charlotte
- Duke Center forSmoking Cessation - Durham
- Duke Center for Smoking Cessation - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01926626
The ClinicalTrials.gov registry entry for NCT01926626 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (59% lower). The listed sponsor is Jed E. Rose, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nicotine Dependence appearing as the primary indexed condition, and to 2 interventions - of which Nicotine Patch is the first listed.
NCT01926626 reports 3 study locations spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01926626 about?
NCT01926626 is a clinical study titled "Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers". The proposed study will assess the efficacy of moclobemide, a selective, reversible MAO-A inhibitor, in facilitating smoking cessation in treatment-seeking female smokers. This rationale is based on several findings from previous work: 1) cigarette smoke contains constituents that inhibit both forms...
What is the current status of trial NCT01926626?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2013-09. Estimated completion is 2014-10.
What conditions does trial NCT01926626 study?
This clinical trial studies the following conditions: Nicotine Dependence.
What interventions are being tested in trial NCT01926626?
The interventions under investigation include: Nicotine Patch (DRUG), Moclobemide (DRUG).
Who is sponsoring clinical trial NCT01926626?
This trial is sponsored by Jed E. Rose, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01926626 being conducted?
This trial has 3 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial of Varenicline for E-cigarette Cessation
RECRUITING · Phase 2
-
Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity
COMPLETED · Phase 2
-
N-acetylcysteine for Tobacco Use Disorder
COMPLETED · Phase 2
-
Targeted Interventions for Weight-Concerned Smokers
COMPLETED · Phase 2
-
Adaptive Pharmacotherapy for Smoking Cessation
COMPLETED · Phase 2
-
E-cigarette Nicotine Study
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.